MARKET

CDTX

CDTX

Cidara Theraptcs
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4621
-0.0208
-4.31%
After Hours: 0.4801 +0.018 +3.90% 16:44 05/18 EDT
OPEN
0.4820
PREV CLOSE
0.4829
HIGH
0.5154
LOW
0.4600
VOLUME
180.34K
TURNOVER
16.21K
52 WEEK HIGH
2.390
52 WEEK LOW
0.4121
MARKET CAP
31.91M
P/E (TTM)
-0.6876
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 2d ago
Read Why HC Wainwright Lowered Price Target On This Small Biotech Stock
U.S. marketing application filing for Cidara Therapeutics Inc's (NASDAQ: CDTX) rezafungin remains on track for mid-2022, setting up a potential early 2023 approval and launch. 
Benzinga · 6d ago
H.C. Wainwright analyst lowers price target on Cidara Therapeutics
H.C. Wainwright Analyst Ed Arce lowered the price target on Cidara Therapeutics (NASDAQ:CDTX) to $6 from $7.50. The Buy rating on CDTX shares was kept. The biotechnology company had reported Q1
Seekingalpha · 6d ago
--HC Wainwright Adjusts Cidara Therapeutics Price Target to $6 From $7.50, Maintains Buy Rating
MT Newswires · 6d ago
Recap: Cidara Therapeutics Q1 Earnings
Cidara Therapeutics (NASDAQ:CDTX) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Benzinga · 05/11 22:34
Cidara Therapeutics (CDTX) Reports Q1 Loss, Lags Revenue Estimates
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -3.85% and 3.93%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/11 21:35
Cidara Therapeutics GAAP EPS of -$0.27 beats by $0.01, revenue of $7.11M beats by $2.4M
Cidara Therapeutics press release (NASDAQ:CDTX): Q1 GAAP EPS of -$0.27 beats by $0.01. Revenue of $7.11M (+195.0% Y/Y) beats by $2.4M. Shares +4.22%.
Seekingalpha · 05/11 20:56
Cidara Therapeutics Q1 EPS $(0.27) Up From $(0.39) YoY, Sales $7.10M Up From $2.41M YoY
Cidara Therapeutics (NASDAQ:CDTX) reported quarterly losses of $(0.27) per share. This is a 30.77 percent increase over losses of $(0.39) per share from the same period last year. The company reported $7.10 million in
Benzinga · 05/11 20:21
More
No Data
Learn about the latest financial forecast of CDTX. Analyze the recent business situations of Cidara Theraptcs through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

37.50%Strong Buy
62.50%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CDTX stock price target is 5.91 with a high estimate of 8.00 and a low estimate of 3.000.
High8.00
Average5.91
Low3.000
Current 0.4621
EPS
Actual
Estimate
-0.25-0.13-0.010.11
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 78
Institutional Holdings: 37.19M
% Owned: 53.85%
Shares Outstanding: 69.05M
TypeInstitutionsShares
Increased
20
6.17M
New
12
10.30M
Decreased
12
468.37K
Sold Out
8
3.30M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.24%
Pharmaceuticals & Medical Research
-2.06%
Key Executives
Non-Executive Chairman/Independent Director
Daniel Burgess
President/Chief Executive Officer/Chief Financial Officer/Director
Jeffrey Stein
Chief Financial Officer
Preetam Shah
Chief Operating Officer
Paul Daruwala
General Counsel/Secretary
Jessica Oien
Other
Taylor Sandison
Independent Director
Bonnie Bassler
Independent Director
Carin Canale - Theakston
Independent Director
Timothy Franson
Independent Director
David Gollaher
Independent Director
Chrysa Mineo
Independent Director
Theodore Schroeder
No Data
No Data
About CDTX
Cidara Therapeutics, Inc. is a biotechnology company. The Company is focused on the discovery, development and commercialization of therapeutics designed for the care of patients facing serious fungal or viral infections. The Company's lead product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. Rezafungin acetate is in Phase III of chemical trials. Its Cloudbreak antiviral platform consist of pipelines to develop Antiviral Conjugates (AVCs) for the prevention and treatment of influenza and other viral infections, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV) and the SARS-CoV-2 strains causing COVID-19. The Company's subsidiary includes Cidara Therapeutics United Kingdom Limited and Cidara Therapeutics (Ireland) Limited.

Webull offers kinds of Cidara Therapeutics Inc stock information, including NASDAQ:CDTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CDTX stock methods without spending real money on the virtual paper trading platform.